BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

CRDF

Cardiff Oncology, Inc.
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$104000−14.0% year on year
$300000$200000$100000$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

100.0%+157.9 pp year on year
200%0%−200%−400%−600%
Q2 ’15Q3 ’16Q3 ’17Q4 ’18Q4 ’19
Company filings · 10-K filed 25 Feb 2021 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$9M−14.7% year on year
$60M$40M$20M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$38M
$20M$0−$20M−$40M
Q1 ’20Q2 ’21Q3 ’22Q3 ’23Q4 ’24
Company filings · 10-K filed 24 Feb 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty